Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,500	266 Pages	Coherent Market Insights	January, 2023	CMI17712935

Best Price Guarantee
Price	from $4,500
Length	266 Pages
Publisher	Coherent Market Insights
Published Date	January, 2023
SKU	CMI17712935

Plasmid DNA Manufacturing Market, By Product Type (Viral Vectors, Plasmid DNA and Non-viral Vectors), By Grade (GMP Grade, R&D Grade and Clinical Grade), By Application (DNA Vaccines, Gene Therapy, Immunotherapy, RNA Vaccines and Others), By Manufacturing Type (Outsourcing and In-house Manufacturing), By Development Phase (Pre-Clinical Therapeutics, Clinical Therapeutics and Marketed Therapeutics), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Circular double-stranded DNA present in the cytoplasm of a bacteria that replicate independently from the bacterial chromosome is called a plasmid DNA. Plasmids are small extra chromosomal DNA molecules within cells that are physically separated from the chromosomal DNA and capable of independent replication. They are most commonly found as small circular double-stranded DNA molecules in bacteria. However, plasmids can be present in archaea and eukaryotes.

Each plasmid has its own "origin of replication". This is a stretch of DNA that ensures it is replicated (copied) by the host bacteria. Because of this, plasmids can copy themselves independently of the bacterial chromosome, and there can be many, possibly hundreds, copies of the plasmid within the bacterial cell.

Market Dynamics

Demand for innovation in existing manufacturing technologies, in order to meet the requirement of appropriate products and its volume is expected to provide immense growth opportunities for key players in the market. For instance, in March 2021, Evolugate, LLC, a Gainesville-based biotech company, has demonstrated that its proprietary technology can be used to improve the throughput of plasmid DNA manufacturing.

The increasing inorganic strategies such as acquisition by the key players in the market to expand product portfolio is expected to drive the market growth over the forecast period. For instance, In January 2022, Aldevron announced the acquisition of Nature Technology Corporation (NTC), a developer of innovative and proprietary plasmid constructs and manufacturing solutions that are used in the field of cell and gene therapy. NTC's nucleic acid-based technologies include Nanoplasmid, a proprietary vector construct that improves the safety and performance of plasmids and biologics.

Key features of the study:

This report provides in-depth analysis of the global plasmid DNA manufacturing market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasmid DNA manufacturing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies Key companies covered as a part of this study include Cobra Biologics and Pharmaceutical Services (Charles River Laboratories), VGXI, Inc., Aldevron (Danaher), Kaneka Corporation, Nature Technology, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy Catapult, LakePharma, Inc., MeiraGTx Limited, Eurofins Genomics, Vigene Biosciences, Luminous BioSciences (LBS), LLC, GenScript, GENEWIZ, Creative Biogene, Akron Biotech, Biomay, JAFRAL Ltd., WuXi Biologics, GeneImmune Biotechnology Corp., Lonza, Greenpak Biotech Ltd., Luina Bio (AcuraBio), Ajinomoto Bio-Pharma, Synbio Technologies, Genopis Inc., Altogen Biosystems, Puresyn, Inc., Cepham Life Sciences, Catalent, Inc., Biomiga, Waisman Biomanufacturing
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global plasmid DNA manufacturing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasmid DNA manufacturing market

Detailed Segmentation:

Global Plasmid DNA Manufacturing Market, By Product Type:
Viral Vectors
Retroviral
Adenoviral
Lentiviral
Adeno Associates
Others
Plasmid DNA
mRNA
Others
Non-viral
Lipid/Polymer
Electroporation
Nanoparticles
Others
Global Plasmid DNA Manufacturing Market, By Grade:
GMP Grade
R&D Grade
Clinical Grade
Global Plasmid DNA Manufacturing Market By Application:
DNA Vaccines
Gene Therapy
Immunotherapy
RNA Vaccines
Others
Global Plasmid DNA Manufacturing Market By Manufacturing Type:
Outsourcing
In-house Manufacturing
Global Plasmid DNA Manufacturing Market By Development Phase:
Pre-Clinical Therapeutics
Clinical Therapeutics
Marketed Therapeutics
Global Plasmid DNA Manufacturing Market, By Region:
North America
By Country:
U.S.
Canada
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Country:
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Country:
India
China
Japan
Australia
ASEAN
South Korea
Rest of Middle East
Middle East
By Country:
GCC
Isreal
Japan
Africa
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Cobra Biologics and Pharmaceutical Services (Charles River Laboratories)*
Company Highlights
Products Portfolio
Key Highlights
Financial Performance
Strategies
VGXI, Inc.
Aldevron (Danaher)
Kaneka Corporation
Nature Technology
PlasmidFactory GmbH & Co. KG
Cell and Gene Therapy Catapult
LakePharma, Inc.
MeiraGTx Limited
Eurofins Genomics
Vigene Biosciences
Luminous BioSciences (LBS), LLC
GenScript
GENEWIZ
Creative Biogene
Akron Biotech
Biomay
JAFRAL Ltd.
WuXi Biologics
GeneImmune Biotechnology Corp.
Lonza
Greenpak Biotech Ltd.
Luina Bio (AcuraBio)
Ajinomoto Bio-Pharma,
Synbio Technologies, Genopis Inc.
Altogen Biosystems, Puresyn, Inc.
Cepham Life Sciences, Catalent, Inc.
Biomiga
Waisman Biomanufacturing

“*” marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions: Research Objectives; Assumptions; Abbreviations
2. Market Purview: Report Description; Market Definition and Scope; Executive Summary; Market Snapshot, By Product Type; Market Snapshot, By Grade; Market Snapshot, By Application; Market Snapshot, By Manufacturing Type; Market Snapshot, By Development Phase; Market Snapshot, By Region; Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis: Market Dynamics; Drivers; Restraints; Market Attractiveness Analysis; Market Opportunities; Product Launches; Merger, Acquisition, Collaborations; Regulatory Guideline and Compliances; Key Developments; PEST Analysis; Technology Landscape; PORTER’s Analysis; Pricing Analysis (2021); Guidelines Specific for the Development of Plasmid DNA Vaccines; Genomic Titer
4. Global Plasmid DNA Manufacturing Market- Impact of Coronavirus (Covid-19) Pandemic: Economic Impact; COVID-19 Epidemiology; Impact on Supply and Demand
5. Global Plasmid DNA Manufacturing Market, By Product Type, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; Viral Vectors; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Retroviral; Adenoviral; Lentiviral; AdenAssociates; Others; Plasmid DNA; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); mRNA; Others; Non-viral; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Lipid/Polymer; Electroporation; Nanoparticles; Others
6. Global Plasmid DNA Manufacturing Market, By Grade, 2017 – 2030, (US$ Million): Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segment Trends; GMP Grade; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); R&D Grade; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Clinical Grade; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
7. Global Plasmid DNA Manufacturing Market, By Application, 2017 – 2030, (US$ Million: Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segments Trends; DNA Vaccines; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Gene Therapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Immunotherapy; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); RNA Vaccines; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Others; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
8. Global Plasmid DNA Manufacturing Market, By Manufacturing Type, 2017 – 2030, (US$ Million: Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segments Trends; Outsourcing; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); In-house Manufacturing; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million)
9. Global Plasmid DNA Manufacturing Market, By Development Phase, 2017 – 2030, (US$ Million: Introduction; Market Share Analysis, 2022 and 2030 (%); Y-o-Y Growth Analysis, 2017 – 2030; Segments Trends; Pre-Clinical Therapeutics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Clinical Therapeutics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); Marketed Therapeutics; Introduction; Market Size and Forecast, and Y-o-Y Growth, 2017–2030, (US$ Million); 10. Global Plasmid DNA Manufacturing Market, By Region, 2017 – 2030, (US$ Million); Introduction; Market Share Analysis, By Region, 2022 and 2030 (%); Y-o-Y Growth Analysis, For Regions, 2017–2030; Regional Trends; North America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); U.S.; Canada; Latin America; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million; Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); Brazil; Mexico; Argentina; Rest of Latin America; Europe; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million; Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); U.K.; Germany; Italy; France; Spain; Russia; Rest of Europe; Asia Pacific; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million; Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); China; India; Japan; ASEAN; Australia; South Korea; Rest of Asia Pacific; Middle East; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million; Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2030, (US$ Million); GCC; Israel; Rest of Middle East; Africa; Introduction; Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Grade, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Manufacturing Type, 2017 - 2030, (US$ Million); Market Size and Forecast, and Y-o-Y Growth, By Development Phase, 2017 - 2030, (US$ Million; Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2017 – 2030, (US$ Million); North Africa; Central Africa; South Africa; 11. Competitive Landscape; Cobra Biologics and Pharmaceutical Services (Charles River Laboratories).*; Company Highlights; Product Portfolio; Key Highlights; Financial Performance; Market Strategies; VGXI, Inc.; Aldevron (Danaher); Kaneka Corporation; Nature Technology; PlasmidFactory GmbH & Co. KG; Cell and Gene Therapy Catapult; LakePharma, Inc.; MeiraGTx Limited; Eurofins Genomics; Vigene Biosciences; Luminous BioSciences (LBS), LLC; GenScript; GENEWIZ; Creative Biogene; Akron Biotech; Biomay; JAFRAL Ltd.; WuXi Biologics; GeneImmune Biotechnology Corp.; Lonza; Greenpak Biotech Ltd.; Luina Bi(AcuraBio); AjinomotBio-Pharma; SynbiTechnologies; Genopis Inc.; Altogen Biosystems; Puresyn, Inc.; Cepham Life Sciences; Catalent, Inc.; Biomiga; Waisman Biomanufacturing; 12. Section; Research Methodology; About Us; *Browse 58 market data tables and 53 figures on “Plasmid DNA Manufacturing Market” - forecast t2030